Latest Breaking News On - ராபர்ட் பிஸ்ஸொன்னெட் - Page 1 : comparemela.com
Dermavant to Showcase PASI90, Itch and Quality of Life Data from Phase 3 Pivotal Trials for Tapinarof at AAD VMX 2021
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Dermavant Sciences: Dermavant Announces Tapinarof Data Presentations at the AAD VMX 2021
Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that two abstracts from Dermavant s two pivotal Phase 3 trials for tapinarof for the treatment of psoriasis in adults, PSOARING 1 and PSOARING 2, will be presented during the upcoming American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX 2021), on April 23-25, 2021.
Tapinarof is being developed as a novel, once-daily therapeutic aryl hydrocarbon receptor modulating agent (TAMA), cosmetically elegant, steroid-free topical cream for the treatment of plaque psoriasis and atopic dermatitis.
The following posters will be viewable on the conference platform for the entirety of the conference:
Dermavant Sciences: Dermavant Announces Tapinarof Data Presentation at the Innovations in Dermatology Conference
Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that an abstract containing interim analysis data from Dermavant s PSOARING 3 long-term, open-label safety study for tapinarof for the treatment of psoriasis in adults will be presented in poster format during the upcoming Innovations in Dermatology Virtual Spring Conference 2021, held from March 16-20, 2021.
The following poster will be viewable on the conference platform for the entirety of the conference:
Title:
Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Interim Analysis of a Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent
Share this article
Share this article
SAN DIEGO, Dec. 11, 2020 /PRNewswire/ Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from the Phase 2b ADVISE trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderate-to-severe atopic dermatitis (AD), will be presented at the Revolutionizing Atopic Dermatitis (RAD) 2020 Virtual Conference. I am pleased to present the topline results from the ADVISE Phase 2 trial which support the rationale for etrasimod as a potential oral, once-daily therapy with a novel mechanism of action for the treatment of atopic dermatitis. I look forward to seeing the advancement of etrasimod to the next phase of clinical development, stated Robert Bissonnette, MD, FRCPC, Founder and CEO, Innovaderm Research. There is a significant unmet clinical need for the development of novel oral therapeutic options for atopic dermatitis pat
vimarsana © 2020. All Rights Reserved.